Although these antibodies can kill CRC cells via a neutralizing effect on EGFR signaling, primary or acquired oncogenic mutations in downstream molecules of the EGFR signaling pathway, e.g., KRAS, BRAF, or PIK3CA, can cause therapeutic resistance to anti-EGFR mAbs [5–8]. The gene discussed is KRAS; the disease is colorectal carcinoma.